DFine Initiates Randomized Clinical Study to Evaluate Advanced Radiofrequency Technology for the Treatment of Spinal Fractures

SAN JOSE, Calif.--(BUSINESS WIRE)--DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced the initiation of a prospective randomized clinical study to evaluate the clinical effectiveness of minimally invasive augmentation procedures to treat debilitating, painful vertebral compression fractures (VCFs). PRIORi-T (Prospective Randomized Investigation Of Radio Frequency Targeted Vertebral Augmentation) is a post-market, clinical study that will compare the radiofrequency targeted vertebral augmentation™ (RF-TVA) procedure to non-operative management (conservative care) in properly diagnosed osteoporotic VCFs within six weeks of onset.